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Abstract
Barrett’s oesophagus is a well-recognised precursor of oesophageal
adenocarcinoma. The incidence of oesophageal adenocarcinoma is continuing
to rise in the Western world with dismal survival rates. In recent years, efforts
have been made to diagnose Barrett’s earlier and improve surveillance
techniques in order to pick up cancerous changes earlier. Recent advances in
endoscopic therapy for early Barrett’s cancers have shifted the paradigm away
from oesophagectomy and have yielded excellent results.
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Introduction
Barrett’s oesophagus (BO) is defined as the replacement of the 
normal distal oesophageal squamous epithelium with metaplastic 
columnar epithelium1. This metaplastic epithelium accumulates 
genetic changes that over time can progress to dysplasia and cancer2. 
Screening for BO with endoscopy remains controversial because of 
poor uptake and lack of cost-effectiveness. A number of alternatives 
have been proposed to remedy the situation: cytosponge, transna-
sal endoscopy (TNE) and oesophageal capsule endoscopy (OCE). 
Surveillance of BO has been demonstrated to diagnose oesopha-
geal cancers earlier and provide a better prognosis3. Surveillance 
has been improved by advances in endoscope technology and tech-
niques, including high-definition endoscopy and chromoendoscopy. 
The advantage of detecting oesophageal neoplasia at an early stage 
is that it can be successfully treated endoscopically without resort-
ing to oesophagectomy.
Screening for Barrett’s oesophagus
There is a lack of high-quality evidence supporting the use of 
conventional endoscopy in population-based screening for BO. 
Ten percent of patients with gastro-oesophageal reflux disease 
(GORD) have BO4. However, even if screening were performed 
for every adult with GORD, 40% of oesophageal adenocarcinomas 
would still be missed5. This has prompted research to identify less 
invasive and more cost-effective and acceptable methods to screen 
for BO, such as cytosponge, TNE and OCE.
Cytosponge
The cytosponge is a sponge contained within a capsule that is 
attached to a string. The capsule is ingested with water and dis-
solves in the stomach after 3 to 5 minutes. The string then is pulled 
to retrieve the sponge and cells collected from the oesophagus6,7. 
The cells are analysed with the biomarker trefoil factor 3 to make 
a diagnosis of BO.
An initial study of the cytosponge6 demonstrated a 3% pickup rate 
of BO in a primary care setting with a majority of patients (82%) 
reporting low levels of anxiety, making it a potential tool for mass 
screening. More recently, Fitzgerald et al. followed up on their work 
with the cytosponge in a large case-control study8. In total, 1,110 
patients were recruited: 463 patients with symptoms of dyspepsia 
and reflux and 647 patients with a prior diagnosis of BO underwent 
gastroscopy following cytosponge examination; 93.9% of patients 
had a successful cytosponge examination. Overall, cytosponge 
sensitivity for detecting BO was 79.9%, increasing to 87.2% in 
patients with more than 3 cm of BO. The specificity for diagnos-
ing BO was 92.4%. Further trials on the cytosponge device are 
ongoing but these data suggest that it is an acceptable and accurate 
device.
Transnasal endoscopy and oesophageal capsule endoscopy
A recent randomised controlled trial compared the use of unsedated 
TNE versus sedated gastroscopy for BO screening. Two hundred 
and nine patients were recruited to standard gastroscopy (surveil-
lance oesophago-gastro-duodenoscopy, or sOGD), unsedated TNE 
in a mobile research van (muTNE) or a hospital outpatient endos-
copy suite (huTNE). Uptake was greater in the unsedated TNE group: 
47.5% for muTNE and 45.7% for huTNE versus 40.7% for standard 
gastroscopy. Complete evaluation of the oesophagus was similar 
between the groups: 99% muTNE, 96% huTNE and 100% sOGD9.
Chak et al.10 examined the acceptability of TNE versus OCE in a 
randomised controlled trial. They found that uptake for screening 
examination was low: 15.2% of patients (n = 1,210). Effectiveness 
of screening for the detection of BO was similar for both technolo-
gies. A meta-analysis11 of studies investigating OCE as a screening 
modality for BO in patients with reflux symptoms demonstrated an 
overall sensitivity of 77% and a specificity of 86%.
Although technology is advancing in the field of BO screening, 
there are insufficient data about its cost-effectiveness. These novel 
approaches appear to be acceptable to patients but more data are 
required to target whom and when to offer screening.
Surveillance for Barrett’s oesophagus
In British guidelines the presence of columnar lined oesopha-
gus alone is considered acceptable for a diagnosis of Barrett’s1. 
American guidelines differ in that they require histological con-
firmation of intestinal metaplasia to confirm a diagnosis of BO12. 
Presence of intestinal metaplasia poses a greater risk of neoplastic 
transformation, and intestinal metaplasia is generally present in 
longer segments of Barrett’s. The current British guidelines recom-
mend that Barrett’s segments of more than 3 cm have a surveil-
lance OGD every 2 to 3 years and segments of less than 3 cm with 
the presence of intestinal metaplasia have surveillance OGD every 
3 to 5 years. Likewise, the American Society for Gastrointestinal 
Endoscopy recommends surveillance OGD every 3 to 5 years.
Endoscopic diagnosis
The annual rate of transformation into oesophageal adenocarci-
noma (OAC) in patients with non-dysplastic BO is estimated to be 
between 0.07% and 0.82%13–15. However, the annual rate of pro-
gression from low-grade dysplasia to high-grade dysplasia (HGD) 
or OAC is as high as 6.5%16–18 and from HGD to OAC is 12% to 
40%19,20. Dysplasia in Barrett’s is often flat, patchy and difficult to 
detect. British Society of Gastroenterology (BSG) guidelines1 rec-
ommend the Seattle biopsy protocol, which entails four-quadrant 
random biopsies every 2 cm in addition to targeted biopsies on 
macroscopically visible lesions. This surveillance method has had a 
poor uptake amongst endoscopists as it is time-consuming, labour-
intensive, and prone to sampling error21,22.
Simple techniques such as mucolytic agents and increased 
inspection times can be used in order to improve visualisation of 
Barrett’s mucosa during surveillance. N-acetylcysteine is a muco-
lytic agent that can be used at a concentration of 4% to 10% to dis-
solve excess mucus and bubbles. Basford et al.23 recently reported 
on a randomised controlled trial (n = 126 patients) comparing a 
combination of simeticone and N-acetylcysteine (NAC) (group A) 
as a pre-drink prior to gastroscopy with water alone (group B) and 
no pre-drink. They reported significant improvement in mucosal 
visibility with simeticone and NAC as compared with just water or 
no pre-drink. This pre-drink was also reported to reduce the number 
of additional flushes to achieve satisfactory views. There is also evi-
dence, in a similar way to colonoscopy, that the longer the duration 
spent assessing BO, the greater the detection rate for neoplasia24. 
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The study suggests spending at least 1 minute per centimetre of 
Barrett’s. However, this study was performed in a high-risk terti-
ary referral population in whom the index of suspicion of neoplasia 
was high, and therefore may not apply to the routine surveillance 
population.
High-definition white light endoscopy
With the advent of charge-coupled device (CCD) chips, high-
definition white light (HDWL) endoscopes are able to capture and 
display high-definition images with pixel densities of more than 
10 million pixels, making standard definition (pixel density of 
100,000 to 400,000) endoscopes obsolete25.
The sensitivity and specificity of HDWL endoscopy in detecting 
Barrett’s neoplasia are 40%–64% and 98%–100%, respectively26,27. 
BSG and American Gastroenterological Association (AGA) guide-
lines recommend the use of high-resolution endoscopes for Barrett’s 
surveillance1,28.
Virtual chromoendoscopy
The enhancement of mucosal surface and vascular patterns using 
optical and digital filter technologies has added to the arsenal of the 
advanced endoscopist in the quest to improve dysplasia detection. 
Narrow band imaging (NBI) (Olympus, Tokyo, Japan) and blue 
laser imaging (BLI) (Fujifilm, Tokyo, Japan) use a filter located in 
front of the light source. This technology filters white light and lim-
its the wavelength of the light projected to 415 to 540 nm29. When 
projected onto a mucosal surface, this ‘narrow band’ of light appears 
blue and green. The blue light penetrates the superficial layer of the 
mucosa, thereby enhancing the view of superficial capillaries and 
the crypt patterns in the mucosal surface. In contrast, technologies 
such as i-Scan (Pentax, Tokyo, Japan) and Fujinon intelligent chro-
moendoscopy (FICE) (Fujinon, Tokyo, Japan) employ complex 
proprietary algorithms to digitally reproduce a narrow-spectrum 
image at the push of a button on the endoscope. BLI30 is a new 
technology with white and blue lasers that produce narrow-band 
light.
Narrow band imaging. NBI is the most studied optical imag-
ing technology thus far and has a sensitivity and specificity of 
47%–100% and 72%–100%, respectively, for detecting Barrett’s 
neoplasia27,31–34. NBI selectively enhances mucosal vascular pat-
terns by narrowing the spectrum of light, reducing the amount of 
red light in the displayed image whilst narrowing the spectrum of 
blue and green, making blood vessels appear dark against the back-
ground mucosa35.
A majority of these studies were conducted in tertiary referral cen-
tres by expert endoscopists evaluating an enriched population with 
a high index of suspicion of neoplasia. The technology has yet to 
be validated in non-expert hands or in a surveillance population. 
Therefore, we would suggest that training in the use of this technol-
ogy and data in a surveillance population be required prior to adop-
tion in routine clinical practice.
i-Scan. i-Scan uses post-processor technology that reconstructs the 
image transmitted from the endoscope by using a computer-based 
algorithm which is able to accentuate both surface patterns and 
vasculature35. A randomised control trial found that the yields of 
acetic acid-guided versus i-Scan-guided biopsies in detecting spe-
cialised columnar epithelium were comparable36. Verna et al. found 
that dysplasia detection rate using this technology was inferior to 
that using the standard four-quadrant biopsy technique37. However, 
these studies were poorly designed and have small sample sizes. 
More robust studies on the utility of i-Scan in the detection of dys-
plasia in BO are required.
Fujinon intelligent chromoendoscopy. FICE uses a CCD in the 
endoscope to capture spectral reflectance data. A matrix process-
ing circuit found in the video processor then receives the data. 
The reflectance spectra of corresponding pixels that make up the 
conventional image are mathematically estimated. From this infor-
mation, a single-wavelength virtual image is reconstructed. Three 
such single-wavelength images can be selected and assigned to the 
red, green and blue monitor inputs to display a composite colour-
enhanced multiband image in real time. This can be used like NBI 
to remove data from the red part of the waveband and narrow the 
green and blue spectra35.
There is a paucity of research evaluating the utility of FICE in detec-
tion of dysplasia in Barrett’s. The sole published study to date is a 
prospective pilot study carried out in a tertiary centre. It was found 
that the dysplasia detection rate of FICE, when used in conjunction 
with acetic acid, is 86%38.
Autofluorescence imaging. Autofluorescence imaging (AFI) is 
based on a principle that a specific light wavelength can cause fluo-
rescence of endogenous biomolecules such as collagen, nicotina-
mide adenine dinucleotide (NADH), flavin adenine dinucleotide 
(FAD), and porphyrins. These molecules can accumulate in dys-
plastic oesophageal mucosa39. A randomised cross-over multi-centre 
trial on an enriched population found a marginal gain of AFI over 
quadrantic biopsies which did not reach statistical significance40. 
Endoscopic trimodal imaging (ETMI) systems which integrate AFI 
with HDWL and NBI have not been shown to be superior to stand-
ard resolution white light endoscopes41,42. With a lack of evidence of 
its efficacy and high false-positive rates, the use of AFI and ETMI at 
present remains in the domain of endoscopic research39–41.
Chromoendoscopy with white light endoscopy
Methylene blue chromoendoscopy. Three randomised cross-over 
trials found that the diagnostic accuracy of methylene blue 
0.5%-directed biopsies is higher than random 2 cm quadrantic 
biopsies43–45. However, a meta-analysis which included data from 
six trials found that overall methylene blue chromoendoscopy was 
not superior to random biopsies in the detection of specialised 
intestinal metaplasia or dysplasia46.
Acetic acid chromoendoscopy. Acetic acid is a weak acid that 
causes acetowhitening of the oesophageal mucosa. Over a period of 
seconds to minutes, dysplastic tissue will start to lose the acetowhit-
ening effect before the surrounding non-dysplastic Barrett’s tissue. 
Differential loss of acetowhitening highlights the neoplastic focus 
as a red spot on a white background (Figure 1). This is an extremely 
promising technique with high sensitivity, universal applicability 
and negligible cost.
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Two large cohort studies have demonstrated effectiveness of acetic 
acid used at concentrations of 2.5% and 1.5%, respectively47,48, in 
the detection of dysplasia within Barrett’s in high-risk populations. 
The two reported similar results, with sensitivities for dysplasia 
between 90% and 95% and specificities between 75% and 85%. 
A further study using 2.5% acetic acid found that the number of 
biopsies needed to detect neoplasia could be significantly reduced 
if acetic acid targeted biopsies were used in place of mapping biop-
sies, thereby reducing pathology-related costs by 97%49. Tholoor 
et al.50 reported the use of 2.5% acetic acid in a surveillance popu-
lation and were able to demonstrate a threefold increase in neo-
plasia detection as compared with conventional protocol-guided 
biopsies. However, this was a non-randomised trial and an ongo-
ing randomised trial, the ABBA study51, will answer this ques-
tion soon. The ABBA study is a randomised, crossover, tandem 
endoscopy study comparing standard quadrantic biopsy protocol 
versus acetic acid targeted biopsies, in a Barrett’s surveillance 
population.
Cross-sectional optical imaging. Optical coherence tomography 
(OCT) and confocal laser endomicroscopy (CLE) are emerging 
technologies that are able to obtain micro-anatomical images of 
the oesophageal mucosa. OCT technology measures the difference 
between the backscatter of near-infrared low-coherence light below 
the tissue surface and a reference beam52. Using this information, it 
is able to reconstruct the microanatomy of the superficial mucosal 
layer53. CLE, on the other hand, involves the integration of a 
confocal laser microscope in the distal tip of a conventional video 
endoscope54. Although both technologies have sensitivities of 68% 
to 86% and specificities of 73% to 83%55,56, the setup costs are high 
and special training is required for image interpretation. This cur-
rently limits its use in routine clinical practice. Table 1 summarises 
the performance of current imaging technologies in the diagnosis 
of Barrett’s neoplasia.
Endotherapy
Until recently, oesophagectomy was regarded as the gold standard 
treatment for patients with HGD or early oesophageal cancer57. 
Even in expert hands, oesophagectomy carries significant morbid-
ity and mortality: 30% to 50% and 2% to 5%, respectively58–60. Not  
only are surgical risks high but the patient population with this con-
dition have co-morbidities that often preclude surgical intervention. 
In the last 15 years, endoscopic therapy has become an established 
treatment of HGD and intramucosal adenocarcinoma (T1a) as the 
risk of lymph node metastases is very low1.
Endoscopic mucosal resection
Experience of endoscopic resection (ER) for early oesophageal ade-
nocarcinoma began in the early 1990s in Asia; since then, techniques 
have significantly progressed. Initial experience came from the strip 
biopsy technique, which was further refined by the suck-and-cut and 
multi-band ligator techniques (Figure 2)61. Ell et al.62 reported the 
Table 1. Performance of current imaging technologies in the diagnosis of 
Barrett’s neoplasia.
Imaging technology Sensitivity Specificity References
High-definition white light 40%–64% 98%–100% 26,27
Narrow band imaging 47%–100% 72%–100% 27,31–34
Autofluorescence imaging 42%–50% 61%–92% 39,73
Methylene blue 49%–51% 48%–85% 44,45
Acetic acid 90%–95% 75%–85% 47,48
Optical coherence tomography 68%–83% 75%–82% 55,74
Confocal laser endoscopy 68%–86% 83%–88% 56
Figure 1. Intramucosal carcinoma (left) and high-grade dysplasia (right) highlighted by acetic acid.
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Figure 2. EMR of Barrett’s HGD. (a) An area of Barrett’s high-grade dysplasia. (b) The same area demonstrating acetowhitening effect. 
(c) The same lesion as viewed down a multi-band ligator. (d) Pseudopolyp created by the band ligator. (e) Resection defect following 
endoscopic mucosal resection.
e
a b
c d
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first (n = 64) series of ER for early Barrett’s cancer, demonstrating 
a 97% remission rate. Despite a short follow-up period (mean of 
12 months), there was a significant rate of recurrence of 14%.
In the early years, a high rate of metachronous and recurrent lesions 
hampered the apparent technical success of ER with reported recur-
rence rates of up to 35%52. This led to a refinement of techniques 
incorporating both endoscopic mucosal resection (EMR) and abla-
tive therapies (discussed below). A randomised trial63 (The APE 
Study) comparing EMR + argon plasma coagulation (APC) ablation 
versus EMR + observation demonstrated a significantly reduced 
risk of metachronous lesions in the ablation arm, 3% versus 37%, 
such that ablation following ER is now standard treatment.
Pech et al.52 reported their outcome data of 1,000 patients with early 
Barrett’s cancer treated by ER, demonstrating a long-term complete 
remission rate of 93.8%. There was a 14.5% recurrence rate, and a 
majority of recurrences were treated endoscopically. Their serious 
complication rate was 1.5%, and no mortality was reported.
Ablative therapies
Given the recognition that ablation following ER offers optimum 
outcomes in terms of neoplasia eradication, it now forms an essential 
component of the treatment pathway of early Barrett’s cancer. The 
two main techniques are APC and radiofrequency ablation (RFA). 
The findings of the APE study63 are described above. A recent meta-
analysis64 of RFA has shown intestinal metaplasia eradication rates 
of 78%, dysplasia eradication rates of 91%, and cancer progression 
rates of 0.2% to 0.5% with an oesophageal stricture rate of 5%. 
Data from the UK RFA registry65 report similar rates of success 
with a complete dysplasia remission rate of 92% and a stricture 
rate of 6.2%.
There are currently no data comparing outcomes of APC and RFA 
to determine which is more effective. However, the Barrett’s Inter-
vention for Dysplasia by Endoscopy (BRIDE) study aims to answer 
this question. Whilst RFA is an extremely effective treatment, its 
costs remain high (up to £1,800 per catheter), and EMR followed 
by intensive acetic acid surveillance has been shown to produce 
outcomes similar to those of the UK RFA registry at a significantly 
cheaper cost66.
Early experience with cryotherapy shows promising results with dys-
plasia eradication rates of up to 97% in patients with short-segment 
BO67. This technology, however, remains firmly in the research 
domain until further data are available.
Endoscopic submucosal dissection
The main limitation of the EMR technique is that en bloc resec-
tion is possible only for lesions of less than 15 mm; lesions larger 
than this require piecemeal resection, making adequate histological 
assessment difficult. Figure 3 demonstrates the steps involved in the 
endoscopic submucosal dissection (ESD) technique. Experience 
with ESD in Japanese studies of early oesophageal squamous cell 
cancer has demonstrated improved outcomes over EMR. To date, 
three European studies have reported outcomes of ESD for neo-
plastic Barrett’s. Neuhaus et al.68 reported on 30 patients with early 
neoplastic lesions up to 30 mm: en bloc resection was achieved in 
90%, the complete neoplasia eradication rate was 96.4%, and there 
were no reported complications. More recently, Chevaux et al.69 
reported on their outcomes of 75 consecutive patients; ESD was 
performed on lesions of more than 15 mm, achieving an en bloc 
resection rate of 90% and a neoplasia eradication rate of 92%, and 
oesophageal strictures developed in 60% of patients. Probst et al.70 
reported on 87 patients with early oesophageal adenocarcinoma 
achieving a 95.4% en bloc resection rate with a recurrence rate of 
2.4%; 11.7% of patients had stricturing, and no perforations were 
reported. Disappointingly, however, these studies have reported low 
R0 resection rates (38.5% to 48.5%).
ESD appears to be a promising addition to current treatment tech-
niques, especially for larger lesions. Our own data on 51 ESDs, on 
selected patients with Barrett’s cancer, have demonstrated an R0 
resection rate for cancer of 88%, a recurrence rate of 3% and no 
complications71. A recently reported randomised controlled trial of 
EMR (n = 20) versus ESD (n = 31) demonstrated superior en bloc, 
R0 and curative resection rates for ESD; however, there was no 
difference in clinical outcome for either technique72. In our experi-
ence, large nodular lesions have a high risk of containing cancer 
and therefore we believe they should be removed in an en bloc 
fashion. Early European data have shown the feasibility and safety 
of ESD in Barrett’s neoplasia but have not proven its superior-
ity over EMR. This has to be addressed in a well-designed study 
for a select group of patients to identify the exact role of ESD in 
Barrett’s neoplasia.
Conclusions
At present, there is insufficient evidence to advocate popula-
tion-based screening, and novel techniques, though acceptable to 
patients, have yet to be proven cost-effective. Inevitably advances 
in endoscope technology will improve dysplasia detection, but we 
believe formalised training programmes are required to extrapo-
late trial evidence from expert endoscopists into everyday practice. 
Outcomes of endotherapy for early Barrett’s neoplasia are excellent 
and should be considered first-line treatment in this group. Increas-
ing experience of ESD in the West will enable en bloc resection 
of larger and more advanced lesions with good outcomes, but fur-
ther trial data are required to clarify who benefits most from this 
technique.
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Figure 3. ESD of Barrett’s IMC. (a) pT1a/M3 intramucosal cancer arising in Barrett’s oesophagus. (b) The same lesion following acetic acid. 
Note the differential early loss of acetowhitening. (c) Edges of the lesion marked with endoscopic submucosal dissection (ESD) knife under 
virtual chromoendoscopy. (d) Submucosal injection. (e) Mucosal incision with ESD knife. (f) Resection base following ESD. (g) Resection 
specimen.
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